IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Lipoprotein(a)
Conditions
Elevated Lipoprotein(a)
Trial Timeline
Apr 1, 2015 → Feb 1, 2016
NCT ID
NCT02414594About IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl)
IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) is a phase 1 stage product being developed by Ionis Pharmaceuticals for Elevated Lipoprotein(a). The current trial status is completed. This product is registered under clinical trial identifier NCT02414594. Target conditions include Elevated Lipoprotein(a).
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02414594 | Phase 1 | Completed |
Competing Products
12 competing products in Elevated Lipoprotein(a)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Olpasiran | Amgen | Phase 1 | 32 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 51 |
| Ivabradine | Amgen | Phase 3 | 76 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 30 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |